Functionally inactivated dominant viral antigens of human cytomegalovirus delivered in replication incompetent adenovirus type 6 vectors as vaccine candidates

Hum Vaccin Immunother. 2017 Dec 2;13(12):2763-2771. doi: 10.1080/21645515.2017.1308988. Epub 2017 May 11.

Abstract

T cell immunity is critical in controlling human cytomegalovirus (HCMV) infection in transplant recipients, and T cells targeting viral immediate early proteins such as IE1, IE2 and pp65 have been speculated to be more effective against reactivation. Here we report efforts to construct replication incompetent adenovirus 6 vectors expressing these viral antigens as vaccine candidates. To reduce the potential liabilities of these viral proteins as vaccine antigens, we introduced mutations to inactivate their reported functions including their nuclear localization signals. The modifications greatly reduced their localization to the nuclei, thus limiting their interactions with cellular proteins important for cell cycle modulation and transactivation. The immunogenicity of modified pp65, IE1 and IE2 vaccines was comparable to their wild-type counterparts in mice and the immunogenicity of the modified antigens was demonstrated in non-human primates.

Keywords: T cell immunity; adenovirus vector; cytomegalovirus (CMV); non-human primate; vaccine.

MeSH terms

  • Animals
  • Antigens, Viral / genetics
  • Antigens, Viral / immunology*
  • Cytomegalovirus / genetics
  • Cytomegalovirus / immunology*
  • Cytomegalovirus Vaccines / administration & dosage
  • Cytomegalovirus Vaccines / adverse effects
  • Cytomegalovirus Vaccines / genetics
  • Cytomegalovirus Vaccines / immunology*
  • Defective Viruses / genetics*
  • Drug Carriers*
  • Female
  • Genetic Vectors*
  • Immediate-Early Proteins / genetics
  • Immediate-Early Proteins / immunology
  • Mastadenovirus / genetics*
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Mutant Proteins / genetics
  • Mutant Proteins / immunology
  • Phosphoproteins / genetics
  • Phosphoproteins / immunology
  • Primates
  • Trans-Activators / genetics
  • Trans-Activators / immunology
  • Vaccines, Synthetic / administration & dosage
  • Vaccines, Synthetic / adverse effects
  • Vaccines, Synthetic / genetics
  • Vaccines, Synthetic / immunology
  • Viral Matrix Proteins / genetics
  • Viral Matrix Proteins / immunology

Substances

  • Antigens, Viral
  • Cytomegalovirus Vaccines
  • Drug Carriers
  • IE1 protein, cytomegalovirus
  • IE2 protein, Cytomegalovirus
  • Immediate-Early Proteins
  • Mutant Proteins
  • Phosphoproteins
  • Trans-Activators
  • Vaccines, Synthetic
  • Viral Matrix Proteins
  • cytomegalovirus matrix protein 65kDa